GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Piotroski F-Score

BeiGene (HKSE:06160) Piotroski F-Score : 4 (As of Mar. 23, 2025)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BeiGene has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for BeiGene's Piotroski F-Score or its related term are showing as below:

HKSE:06160' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 6
Current: 4

During the past 12 years, the highest Piotroski F-Score of BeiGene was 6. The lowest was 3. And the median was 3.


BeiGene Piotroski F-Score Historical Data

The historical data trend for BeiGene's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Piotroski F-Score Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 6.00 3.00 3.00 4.00

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 4.00

Competitive Comparison of BeiGene's Piotroski F-Score

For the Biotechnology subindustry, BeiGene's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where BeiGene's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was -1964.746 + -940.363 + -945.438 + -1180.632 = HK$-5,031 Mil.
Cash Flow from Operations was -2413.959 + -746.542 + 1467.583 + 584.249 = HK$-1,109 Mil.
Revenue was 5880.174 + 7256.786 + 7803.458 + 8767.027 = HK$29,707 Mil.
Gross Profit was 4902.807 + 6177.976 + 6475.388 + 7518.93 = HK$25,075 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(45338.037 + 44338.268 + 44612.118 + 45428.23 + 46025.602) / 5 = HK$45148.451 Mil.
Total Assets at the begining of this year (Dec23) was HK$45,338 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,638 Mil.
Total Current Assets was HK$31,028 Mil.
Total Current Liabilities was HK$17,217 Mil.
Net Income was -2734.73 + -2985.446 + 1686.361 + -2870.515 = HK$-6,904 Mil.

Revenue was 3514.656 + 4662.679 + 6116.47 + 4954.607 = HK$19,248 Mil.
Gross Profit was 2872.718 + 3910.79 + 5362.515 + 4128.081 = HK$16,274 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(49665.324 + 46752.94 + 44873.189 + 43251.515 + 45338.037) / 5 = HK$45976.201 Mil.
Total Assets at the begining of last year (Dec22) was HK$49,665 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,717 Mil.
Total Current Assets was HK$32,828 Mil.
Total Current Liabilities was HK$14,137 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BeiGene's current Net Income (TTM) was -5,031. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

BeiGene's current Cash Flow from Operations (TTM) was -1,109. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-5031.179/45338.037
=-0.11097038

ROA (Last Year)=Net Income/Total Assets (Dec22)
=-6904.33/49665.324
=-0.13901711

BeiGene's return on assets of this year was -0.11097038. BeiGene's return on assets of last year was -0.13901711. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

BeiGene's current Net Income (TTM) was -5,031. BeiGene's current Cash Flow from Operations (TTM) was -1,109. ==> -1,109 > -5,031 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1638.33/45148.451
=0.03628762

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1717.133/45976.201
=0.0373483

BeiGene's gearing of this year was 0.03628762. BeiGene's gearing of last year was 0.0373483. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=31028.249/17217.296
=1.80215575

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=32827.823/14136.621
=2.32218314

BeiGene's current ratio of this year was 1.80215575. BeiGene's current ratio of last year was 2.32218314. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

BeiGene's number of shares in issue this year was 1391.337. BeiGene's number of shares in issue last year was 1352.961. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=25075.101/29707.445
=0.84406791

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=16274.104/19248.412
=0.84547775

BeiGene's gross margin of this year was 0.84406791. BeiGene's gross margin of last year was 0.84547775. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=29707.445/45338.037
=0.6552433

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=19248.412/49665.324
=0.3875624

BeiGene's asset turnover of this year was 0.6552433. BeiGene's asset turnover of last year was 0.3875624. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

BeiGene has an F-score of 4 indicating the company's financial situation is typical for a stable company.

BeiGene  (HKSE:06160) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


BeiGene Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of BeiGene's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Traded in Other Exchanges
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines